The FDA has approved Capvaxive for the prevention of pneumococcal disease in at-risk children and adolescents.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for CAPVAXIVE ® ...

Vaccinations used to seem simple. Your doctor would tell you which to get, and you’d roll up your sleeve at the office or a nearby pharmacy. Now we’re seeing changing recommendations, and some people ...

A new vaccine for pneumococcal disease will be tested under an international trial aiming to provide greater protection to babies against the common infection that causes pneumonia, sinusitis and ...